Truist Financial Lowers PT on LendingTree (TREE) to $60, Retains a Buy Rating
LendingTree, Inc. (NASDAQ:TREE) is one of the 13 Small Cap Stocks Analysts Are Bullish On. In a report released on May 5, Youssef Squali from Truist Financial maintained a Buy rating on LendingTree, Inc. (NASDAQ:TREE), lowering the firm's price target to $60 from $72. The rating update came after the company reported 'mixed' fiscal Q1 2025 results and guidance.
A happily married couple discussing the merits of different home equity loan options.
Truist Financial expressed optimistic sentiments for the stock, stating that factors like LendingTree, Inc.'s (NASDAQ:TREE) well-diversified revenue base, scale, and valuation make it a lucrative play amid the ongoing recovery in Insurance.
The analyst told investors in a research note that the firm also expects the Home and Consumer segment to undergo recovery over time as rates normalize. LendingTree, Inc.'s (NASDAQ:TREE) balance sheet is another factor supporting the positive rating, as it is adequate to support the current business, according to the analyst.
LendingTree, Inc. (NASDAQ:TREE) operates an online loan marketplace for consumers looking for loans and other credit-based offerings. The company's operations are divided into three segments: Home, Consumer, and Insurance.
While we acknowledge the potential of TREE as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
READ NEXT: The Best and Worst Dow Stocks for the Next 12 Months and 10 Unstoppable Stocks That Could Double Your Money.
Disclosure: None.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
TPXimpact Holdings Full Year 2025 Earnings: UK£0.10 loss per share (vs UK£0.24 loss in FY 2024)
Revenue: UK£77.3m (down 8.2% from FY 2024). Net loss: UK£9.16m (loss narrowed by 59% from FY 2024). UK£0.10 loss per share (improved from UK£0.24 loss in FY 2024). Trump has pledged to "unleash" American oil and gas and these 15 US stocks have developments that are poised to benefit. All figures shown in the chart above are for the trailing 12 month (TTM) period TPXimpact Holdings shares are up 2.6% from a week ago. Before we wrap up, we've discovered 3 warning signs for TPXimpact Holdings (1 doesn't sit too well with us!) that you should be aware of. Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Associated Press
39 minutes ago
- Associated Press
Forte Biosciences Announces Pricing of $75 Million Public Offering
DALLAS--(BUSINESS WIRE)--Jun 25, 2025-- Forte Biosciences, Inc. (Nasdaq: FBRX), a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases, today announced the pricing of a public offering of 5,630,450 shares of its common stock at a price to the public of $12.00 per share and, in lieu of common stock to certain investors who so chose, pre-funded warrants to purchase up to 619,606 shares of common stock at a price to the public of $11.999 per pre-funded warrant, which represents the per share public offering price of each share of common stock less the $0.001 per share exercise price for each pre-funded warrant. In addition, Forte has granted the underwriters a 30-day option to purchase up to an additional 937,508 shares of its common stock at the public offering price, less the underwriting discounts and commissions. All of the shares of common stock and pre-funded warrants are being offered by Forte. The gross proceeds from the offering are expected to be approximately $75 million before deducting underwriting discounts and commissions and other offering expenses. The offering is expected to close on or about June 26, 2025, subject to satisfaction of customary closing conditions. Forte intends to use the net proceeds of the offering for working capital and other general corporate purposes, which includes funding clinical and preclinical development of its product candidate and other research activities. TD Cowen, Evercore ISI, Guggenheim Securities and Chardan are acting as joint book-running managers for the offering. Lucid Capital Markets and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as co-managers for the offering. The offering is being made pursuant to a Registration Statement on Form S-3 (File No. 333-286226), including a base prospectus, previously filed with and declared effective by the SEC. A preliminary prospectus supplement and accompanying prospectus relating to and describing the terms of the offering has been filed with the SEC. A final prospectus supplement and accompanying prospectus relating to the offering will also be filed with the SEC. These documents can be accessed for free through the SEC's website at Copies of the final prospectus supplement and accompanying prospectus relating to the offering, when available, may also be obtained from TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, by telephone at (855) 495-9846 or by email at [email protected], Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, NY 10055, by telephone at (888)-474-0200, or by email at [email protected], Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, by telephone at (212) 518-9544, or by email at [email protected], and Chardan Capital Markets, LLC, One Pennsylvania Plaza, Suite 4800, New York, NY 10119. This press release shall not constitute an offer to sell or the solicitation of an offer to buy the securities being offered, nor shall there be any sale of the securities being offered in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction. About Forte Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company that is advancing FB102, which is a proprietary anti-CD122 monoclonal antibody therapeutic candidate with potentially broad autoimmune and autoimmune-related indications. Forward Looking Statements Forte cautions you that statements included in this press release that are not a description of historical facts are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as 'may,' 'will,' 'should,' 'expect,' 'plan,' 'anticipate,' 'could,' 'intend,' 'target,' 'project,' 'contemplates,' 'believes,' 'estimates,' 'predicts,' 'potential' or 'continue' or the negatives of these terms or other similar expressions. These statements are based on the Forte's current beliefs and expectations. Forward-looking statements include statements regarding the completion and timing of the offering and the anticipated use of proceeds from the offering. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation: whether or not Forte will be able to raise capital through the sale of securities or consummate the offering; the final terms of the offering; the satisfaction of customary closing conditions; prevailing market conditions; general economic and market conditions as well as geopolitical developments; and other risks. Additional risks, uncertainties, and other information affecting Forte's business and operating results are contained in Forte's Quarterly Report on Form 10-Q filed on May 15, 2025, and in its other filings with the Securities and Exchange Commission. All forward-looking statements in this press release are current only as of the date hereof and, except as required by applicable law, Forte undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise. All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. Source: Forte Biosciences, Inc. View source version on CONTACT: Forte Biosciences, Inc. [email protected] KEYWORD: UNITED STATES NORTH AMERICA TEXAS INDUSTRY KEYWORD: BIOTECHNOLOGY GENERAL HEALTH INFECTIOUS DISEASES HEALTH PHARMACEUTICAL SOURCE: Forte Biosciences, Inc. Copyright Business Wire 2025. PUB: 06/25/2025 12:28 AM/DISC: 06/25/2025 12:27 AM
Yahoo
40 minutes ago
- Yahoo
Modine (MOD) Outperforms Broader Market: What You Need to Know
Modine (MOD) closed at $99.93 in the latest trading session, marking a +2.84% move from the prior day. The stock's performance was ahead of the S&P 500's daily gain of 1.11%. Meanwhile, the Dow experienced a rise of 1.19%, and the technology-dominated Nasdaq saw an increase of 1.43%. Shares of the heating and cooling products maker have appreciated by 8.2% over the course of the past month, outperforming the Auto-Tires-Trucks sector's gain of 0.34%, and the S&P 500's gain of 3.92%. The investment community will be closely monitoring the performance of Modine in its forthcoming earnings report. The company is forecasted to report an EPS of $0.98, showcasing a 5.77% downward movement from the corresponding quarter of the prior year. Alongside, our most recent consensus estimate is anticipating revenue of $654.07 million, indicating a 1.12% downward movement from the same quarter last year. In terms of the entire fiscal year, the Zacks Consensus Estimates predict earnings of $4.51 per share and a revenue of $2.73 billion, indicating changes of +11.36% and +5.77%, respectively, from the former year. It's also important for investors to be aware of any recent modifications to analyst estimates for Modine. These latest adjustments often mirror the shifting dynamics of short-term business patterns. Consequently, upward revisions in estimates express analysts' positivity towards the business operations and its ability to generate profits. Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To capitalize on this, we've crafted the Zacks Rank, a unique model that incorporates these estimate changes and offers a practical rating system. The Zacks Rank system, spanning from #1 (Strong Buy) to #5 (Strong Sell), boasts an impressive track record of outperformance, audited externally, with #1 ranked stocks yielding an average annual return of +25% since 1988. Over the past month, there's been a 1.53% fall in the Zacks Consensus EPS estimate. At present, Modine boasts a Zacks Rank of #3 (Hold). In terms of valuation, Modine is presently being traded at a Forward P/E ratio of 21.53. This represents a premium compared to its industry average Forward P/E of 12.12. We can additionally observe that MOD currently boasts a PEG ratio of 0.63. The PEG ratio is similar to the widely-used P/E ratio, but this metric also takes the company's expected earnings growth rate into account. The Automotive - Original Equipment industry currently had an average PEG ratio of 1.07 as of yesterday's close. The Automotive - Original Equipment industry is part of the Auto-Tires-Trucks sector. At present, this industry carries a Zacks Industry Rank of 74, placing it within the top 31% of over 250 industries. The Zacks Industry Rank assesses the vigor of our specific industry groups by computing the average Zacks Rank of the individual stocks incorporated in the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1. Make sure to utilize to follow all of these stock-moving metrics, and more, in the coming trading sessions. Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Modine Manufacturing Company (MOD) : Free Stock Analysis Report This article originally published on Zacks Investment Research ( Zacks Investment Research
